Diabetes Screening for Patients on Antipsychotic Medications

This report is a technical document that presents findings on diabetes screening for individuals with schizophrenia or bipolar disorder who are prescribed antipsychotic medications, focusing on the 2020 measurement year. It outlines the importance of routine diabetes screening due to the elevated risk of type 2 diabetes mellitus (T2DM) in this population, which is exacerbated by the use of atypical antipsychotic agents. The report details the methodology used to measure screening rates, employing the Healthcare Effectiveness Data and Information Set (HEDIS®) standard measure, specifically NQF 1932. It highlights the disparities in screening rates based on geographical regions and types of health insurance coverage. The analysis included a diverse patient population, leveraging data from the Centers for Medicare & Medicaid Services (CMS) and Komodo Health’s extensive all-payer data assets. The findings indicate that a significant portion of patients do not receive the necessary screenings, emphasizing the need for ongoing measurement and analysis of healthcare performance in this area.